Transfusion Service
DENESE MARKS, PhD
Research Program Leader- Product Development
Australian Red Cross Lifeblood
Alexandria, New South Wales, Australia
Disclosure(s): Vitrafy Life Sciences: Consultant/Advisory Board (Ongoing), Grant/Research Support (Ongoing)
DENESE MARKS, PhD
Research Program Leader- Product Development
Australian Red Cross Lifeblood
Alexandria, New South Wales, Australia
Disclosure(s): Vitrafy Life Sciences: Consultant/Advisory Board (Ongoing), Grant/Research Support (Ongoing)
Michael Reade, MBBS MPH DPhil DMedSc (he/him/his)
Director, Greater Brisbane Clinical School
University of Queensland
Brisbane, Queensland, Australia
Disclosure(s): No financial relationships to disclose
Session Desription: This session will explore the characteristics of cryopreserved platelets from laboratory studies, followed by the first presentation of the results from the CLIP-II clinical trial. The CLIP-II trial is a phase III multicentre blinded randomised controlled clinical non-inferiority trial of cryopreserved platelets versus conventional liquid-stored platelets for the management of surgical bleeding. In the first presentation, laboratory investigations of the functional qualities of cryopreserved platelets and their haemostatic capacity will be described. Production methods of cryopreserved platelets, management of an inventory of cryopreserved platelets and health economic considerations will also be discussed. The session will then move to presentation of the outcomes of the CLIP-II trial, with emphasis on how they may change transfusion practice, particularly for bleeding patients. Data from other trials will also be explored, which suggest cryopreserved platelets may be less effective than expected for indications such as correcting a low platelet count in non-bleeding patients. This will be the first time that the results of the CLIP-II trial are presented.